Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13853539 | 0.91 | MAPT (0.48) | MAPTNAMPTEPHX1EPHX2KDM4E | |
| SCHEMBL25808542 | 0.81 | MTNR1A (0.44) | MAPTNAMPTDRD2DRD3MAPK1 | |
| SCHEMBL5740884 | 0.81 | MTNR1A (0.44) | MAPTNAMPTDRD2DRD3MAPK1 | |
| SCHEMBL856649 | 0.81 | CYP2D6 (0.44) | MAPTNAMPTDRD2DRD3MAPK1 | |
| SCHEMBL31420630 | 0.81 | CYP2D6 (0.44) | MAPTNAMPTDRD2DRD3MAPK1 | |
| SCHEMBL20807877 | 0.81 | EPHX2 (0.51) | MAPTEPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL20666080 | 0.81 | MAPT (0.41) | MAPTNAMPTDRD2DRD3EPHX1 | |
| SCHEMBL3937928 | 0.80 | NAMPT (0.42) | MAPTNAMPTDRD2DRD3EPHX1 | |
| SCHEMBL14365983 | 0.79 | BRD4 (0.53) | MAPTEPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL22169743 | 0.79 | SSTR4 (0.48) | MAPTNAMPTDRD2DRD3SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | NUVATION BIO INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-01-24 | — | — | US | disclosed |
| US-20100137361-A1 | Tetrahydro-Quinolinylurea Derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-03 | — | — | US | disclosed |
| US-7683076-B2 | Tetrahydro-quinolinylurea derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-03-23 | — | — | US | disclosed |
| US-7615557-B2 | Tetrahydro-naphthalene and urea derivatives | XENTION LIMITED (GB) | 2009-11-10 | — | — | US | disclosed |
| US-20090163506-A1 | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | SMITHKLINE BEECHAM PLC. (GB) | 2009-06-25 | — | — | US | disclosed |
| US-7528151-B2 | Heterocyclic urea derivatives for the treatment of pain | GLAXO GROUP LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| US-7390817-B2 | Combinations of a vanilloid antagonist and an NSAID for the treatment of pain | GLAXO GROUP LIMITED (GB) | 2008-06-24 | — | — | US | disclosed |
| US-20080058377-A1 | Bicyclic Amide, Carbamate or Urea Derivatives as Vanilloid Receptor Modulators | BAYER HEALTHCARE AG (DE) | 2008-03-06 | — | — | US | disclosed |
| US-20080045546-A1 | Tetradydro-Naphthalene And Urea Derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-02-21 | — | — | US | disclosed |
| US-20070213363-A1 | Tetrahydro-Quinolinylurea Derivatives | BAYER HEALTHCARE AG (DE) | 2007-09-13 | — | — | US | disclosed |
| US-20070167458-A1 | Tetrahydro-naphthalene and urea derivatives | BAYER HEALTHCARE AG (DE) | 2007-07-19 | — | — | US | disclosed |
| US-20070117820-A1 | Heterocyclic urea derivatives for the treatment of pain | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117820-A1 | Heterocyclic urea derivatives for the treatment of pain | U2SURP, UMPS, SFPQ | MAPT 1303/4885NAMPT 2194/4885DRD2 1760/4885 |
| US-20070213363-A1 | Tetrahydro-Quinolinylurea Derivatives | NMUR1, OPRL1, NQO2 | MAPT 2696/4885NAMPT 820/4885DRD2 445/4885 |
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | MAPT 4850/4885NAMPT 397/4885DRD2 569/4885 |
| US-20080058377-A1 | Bicyclic Amide, Carbamate or Urea Derivatives as Vanilloid Receptor Modulators | NMUR1, CNR1, AVPR1A | MAPT 2061/4885NAMPT 1071/4885DRD2 966/4885 |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | ADORA2A, ADORA3, ADORA1 | MAPT 4850/4885NAMPT 397/4885DRD2 569/4885 |
| US-20070167458-A1 | Tetrahydro-naphthalene and urea derivatives | NQO2, UGT1A4, CYP4B1 | MAPT 1696/4885NAMPT 1117/4885DRD2 2687/4885 |
| US-20090163506-A1 | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | TRPV1, OPRL1, UTS2R | MAPT 2168/4885NAMPT 2318/4885DRD2 917/4885 |
| US-20100137361-A1 | Tetrahydro-Quinolinylurea Derivatives | NMUR1, OPRL1, HVCN1 | MAPT 2668/4885NAMPT 699/4885DRD2 446/4885 |
| US-20080045546-A1 | Tetradydro-Naphthalene And Urea Derivatives | NMUR1, GPR17, NMUR2 | MAPT 949/4885NAMPT 1461/4885DRD2 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.